论文部分内容阅读
目的观察盐酸法舒地尔联合依达拉奉治疗外伤性脑梗死(PTCI)的临床疗效及安全性。方法 80例PTCI患者随机分成治疗组和对照组,每组40例。对照组予甘露醇、低分子右旋糖酐、舒血宁注射液等治疗;治疗组加用盐酸法舒地尔30mg及依达拉奉30mg,每天2次,静脉滴注,疗程为2周。治疗前和治疗后14d、28d根据格拉斯哥昏迷评分(GCS)评定脑损伤严重程度,随访3个月根据格拉斯哥预后评分(GOS)评定临床疗效。结果 2组治疗后GCS及GOS评分均有改善,治疗组明显优于对照组(P<0.05);2组均未见严重不良反应。结论盐酸法舒地尔联合依达拉奉治疗外伤性脑梗死能提高临床疗效,改善预后,安全性高。
Objective To observe the clinical efficacy and safety of fasudil combined with edaravone in the treatment of traumatic cerebral infarction (PTCI). Methods 80 patients with PTCI were randomly divided into treatment group and control group, 40 cases in each group. The control group was treated with mannitol, low molecular dextran and Shuxuening injection. The treatment group was given Fasudil Hydrochloride 30mg and Edaravone 30mg twice daily by intravenous drip for 2 weeks. The severity of brain injury was assessed according to Glasgow Coma Scale (GCS) before treatment and 14d and 28d after treatment. The clinical efficacy was assessed according to the Glasgow Outcome Scale (GOS) at 3 months of follow-up. Results The GCS and GOS scores of both groups were improved after treatment, and the treatment group was significantly better than the control group (P <0.05). No serious adverse reactions were found in the two groups. Conclusion Fasudil hydrochloride combined with edaravone in the treatment of traumatic cerebral infarction can improve the clinical curative effect, improve prognosis and high safety.